Wong E, Barr R M, Brain S D, Greaves M W, Olins L A, Mallet A I
Br J Clin Pharmacol. 1984 Oct;18(4):523-7. doi: 10.1111/j.1365-2125.1984.tb02499.x.
Eight psoriatic patients were treated with etretinate (50 mg daily) for 6 weeks. Skin chamber exudates from involved and uninvolved skin were assayed for arachidonic acid, 12-HETE, PGE2 and for neutrophil chemokinetic activity co-chromatographing with leukotriene B4, before and at weekly intervals during therapy. Pre-treatment concentrations of arachidonic acid, 12-HETE and leukotriene B4-like chemokinetic activity but not of PGE2 were elevated in involved skin when compared to uninvolved skin. The concentrations of arachidonic acid and 12-HETE declined during therapy but changes in PGE2 were minimal. LTB4-like activity was detectable in involved skin both before and after etretinate treatment. Clinically, scaling and infiltration improved but erythema was still evident.
8例银屑病患者接受依曲替酯(每日50毫克)治疗6周。在治疗前及治疗期间每周一次,对受累皮肤和未受累皮肤的皮肤腔渗出物进行花生四烯酸、12-羟基二十碳四烯酸(12-HETE)、前列腺素E2(PGE2)检测,并与白三烯B4进行共色谱分析以检测中性粒细胞趋化活性。与未受累皮肤相比,受累皮肤中花生四烯酸、12-HETE和白三烯B4样趋化活性的预处理浓度升高,但PGE2浓度未升高。治疗期间花生四烯酸和12-HETE的浓度下降,但PGE2的变化最小。在依曲替酯治疗前后,受累皮肤中均可检测到白三烯B4样活性。临床上,鳞屑和浸润有所改善,但红斑仍很明显。